APO Research
Talk to an analyst

APO RESEARCH · REPORT

NGS Tumor Gene Analysis Software

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global NGS Tumor Gene Analysis Software Market Analysis and Forecast 2026-2032

5 July 2026173 pages

Choose your research edition.

Industry ResearchNGS Tumor Gene Analysis Software Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal NGS Tumor Gene Analysis Software Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal NGS Tumor Gene Analysis Software Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NGS Tumor Gene Analysis Software Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal NGS Tumor Gene Analysis Software Market Analysis and Forecast 2026-2032173 pages · $4,950 USD

Market perspective

The global NGS Tumor Gene Analysis Software market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for NGS Tumor Gene Analysis Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for NGS Tumor Gene Analysis Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for NGS Tumor Gene Analysis Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for NGS Tumor Gene Analysis Software is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of NGS Tumor Gene Analysis Software include Roche, Illumina, Thermo Fisher Scientific, BGI Group, Novogene, Geneseeq, AmoyDx, Burning Rock Medicine and GTH.O, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for NGS Tumor Gene Analysis Software, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of NGS Tumor Gene Analysis Software, also provides the revenue of main regions and countries. Of the upcoming market potential for NGS Tumor Gene Analysis Software, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the NGS Tumor Gene Analysis Software revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global NGS Tumor Gene Analysis Software market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for NGS Tumor Gene Analysis Software revenue, projected growth trends, production technology, application and end-user industry.

NGS Tumor Gene Analysis Software Segment by Company

Roche

Illumina

Thermo Fisher Scientific

BGI Group

Novogene

Geneseeq

AmoyDx

Burning Rock Medicine

GTH.O

Golden Helix, Inc

Diatech Pharmacogenetics

ViennaLab Diagnostics GmbH

3D Medicines

NGS Tumor Gene Analysis Software Segment by Type

Non-Small Cell Lung Cancer

Human 6 Gene Mutations

Human 12 Gene Mutations

Other

NGS Tumor Gene Analysis Software Segment by Application

Hospitals and Health Systems

Research Institute

Other

NGS Tumor Gene Analysis Software Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NGS Tumor Gene Analysis Software market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NGS Tumor Gene Analysis Software and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NGS Tumor Gene Analysis Software.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of NGS Tumor Gene Analysis Software in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of NGS Tumor Gene Analysis Software company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, NGS Tumor Gene Analysis Software revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global NGS Tumor Gene Analysis Software Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Non-Small Cell Lung Cancer Major Player Table 3. Human 6 Gene Mutations Major Player Table 4. Human 12 Gene Mutations Major Player Table 5. Other Major Player Table 6. Global NGS Tumor Gene Analysis Software Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospitals and Health Systems Major Player Table 8. Research Institute Major Player Table 9. Other Major Player Table 10. NGS Tumor Gene Analysis Software Industry Trends Table 11. NGS Tumor Gene Analysis Software Industry Drivers Table 12. NGS Tumor Gene Analysis Software Industry Opportunities and Challenges Table 13. NGS Tumor Gene Analysis Software Industry Restraints Table 14. Global NGS Tumor Gene Analysis Software Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global NGS Tumor Gene Analysis Software Market Size by Region (2021-2026) & (US$ Million) Table 16. Global NGS Tumor Gene Analysis Software Market Share by Region (2021-2026) Table 17. Global NGS Tumor Gene Analysis Software Market Size by Region (2027-2032) & (US$ Million) Table 18. Global NGS Tumor Gene Analysis Software Market Share by Region (2027-2032) Table 19. Global NGS Tumor Gene Analysis Software Revenue by Players (US$ Million) & (2021-2026) Table 20. Global NGS Tumor Gene Analysis Software Revenue Market Share by Players (2021-2026) Table 21. Global NGS Tumor Gene Analysis Software Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global NGS Tumor Gene Analysis Software Key Players Headquarters & Area Served Table 23. Global NGS Tumor Gene Analysis Software Players, Product Type & Application Table 24. Global NGS Tumor Gene Analysis Software Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global NGS Tumor Gene Analysis Software by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global NGS Tumor Gene Analysis Software Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global NGS Tumor Gene Analysis Software Revenue by Type (2021-2026) & (US$ Million) Table 29. Global NGS Tumor Gene Analysis Software Revenue by Type (2027-2032) & (US$ Million) Table 30. Global NGS Tumor Gene Analysis Software Revenue Market Share by Type (2021-2026) Table 31. Global NGS Tumor Gene Analysis Software Revenue Market Share by Type (2027-2032) Table 32. Global NGS Tumor Gene Analysis Software Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global NGS Tumor Gene Analysis Software Revenue by Application (2021-2026) & (US$ Million) Table 34. Global NGS Tumor Gene Analysis Software Revenue by Application (2027-2032) & (US$ Million) Table 35. Global NGS Tumor Gene Analysis Software Revenue Market Share by Application (2021-2026) Table 36. Global NGS Tumor Gene Analysis Software Revenue Market Share by Application (2027-2032) Table 37. Roche Company Information Table 38. Roche Business Overview Table 39. Roche NGS Tumor Gene Analysis Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Roche NGS Tumor Gene Analysis Software Product Portfolio Table 41. Roche Recent Development Table 42. Illumina Company Information Table 43. Illumina Business Overview Table 44. Illumina NGS Tumor Gene Analysis Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Illumina NGS Tumor Gene Analysis Software Product Portfolio Table 46. Illumina Recent Development Table 47. Thermo Fisher Scientific Company Information Table 48. Thermo Fisher Scientific Business Overview Table 49. Thermo Fisher Scientific NGS Tumor Gene Analysis Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Thermo Fisher Scientific NGS Tumor Gene Analysis Software Product Portfolio Table 51. Thermo Fisher Scientific Recent Development Table 52. BGI Group Company Information Table 53. BGI Group Business Overview Table 54. BGI Group NGS Tumor Gene Analysis Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. BGI Group NGS Tumor Gene Analysis Software Product Portfolio Table 56. BGI Group Recent Development Table 57. Novogene Company Information Table 58. Novogene Business Overview Table 59. Novogene NGS Tumor Gene Analysis Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Novogene NGS Tumor Gene Analysis Software Product Portfolio Table 61. Novogene Recent Development Table 62. Geneseeq Company Information Table 63. Geneseeq Business Overview Table 64. Geneseeq NGS Tumor Gene Analysis Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Geneseeq NGS Tumor Gene Analysis Software Product Portfolio Table 66. Geneseeq Recent Development Table 67. AmoyDx Company Information Table 68. AmoyDx Business Overview Table 69. AmoyDx NGS Tumor Gene Analysis Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. AmoyDx NGS Tumor Gene Analysis Software Product Portfolio Table 71. AmoyDx Recent Development Table 72. Burning Rock Medicine Company Information Table 73. Burning Rock Medicine Business Overview Table 74. Burning Rock Medicine NGS Tumor Gene Analysis Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Burning Rock Medicine NGS Tumor Gene Analysis Software Product Portfolio Table 76. Burning Rock Medicine Recent Development Table 77. GTH.O Company Information Table 78. GTH.O Business Overview Table 79. GTH.O NGS Tumor Gene Analysis Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. GTH.O NGS Tumor Gene Analysis Software Product Portfolio Table 81. GTH.O Recent Development Table 82. Golden Helix, Inc Company Information Table 83. Golden Helix, Inc Business Overview Table 84. Golden Helix, Inc NGS Tumor Gene Analysis Software Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Golden Helix, Inc NGS Tumor Gene Analysis Software Product Portfolio Table 86. Golden Helix, Inc Recent Development Table 87. Diatech Pharmacogenetics Company Information Table 88. Diatech Pharmacogenetics Business Overview Table 89. Diatech Pharmacogenetics NGS Tumor Gene Analysis Software Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. Diatech Pharmacogenetics NGS Tumor Gene Analysis Software Product Portfolio Table 91. Diatech Pharmacogenetics Recent Development Table 92. ViennaLab Diagnostics GmbH Company Information Table 93. ViennaLab Diagnostics GmbH Business Overview Table 94. ViennaLab Diagnostics GmbH NGS Tumor Gene Analysis Software Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. ViennaLab Diagnostics GmbH NGS Tumor Gene Analysis Software Product Portfolio Table 96. ViennaLab Diagnostics GmbH Recent Development Table 97. 3D Medicines Company Information Table 98. 3D Medicines Business Overview Table 99. 3D Medicines NGS Tumor Gene Analysis Software Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. 3D Medicines NGS Tumor Gene Analysis Software Product Portfolio Table 101. 3D Medicines Recent Development Table 102. North America NGS Tumor Gene Analysis Software Revenue by Type (2021-2026) & (US$ Million) Table 103. North America NGS Tumor Gene Analysis Software Revenue by Type (2027-2032) & (US$ Million) Table 104. North America NGS Tumor Gene Analysis Software Revenue by Application (2021-2026) & (US$ Million) Table 105. North America NGS Tumor Gene Analysis Software Revenue by Application (2027-2032) & (US$ Million) Table 106. North America NGS Tumor Gene Analysis Software Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. North America NGS Tumor Gene Analysis Software Revenue by Country (2021-2026) & (US$ Million) Table 108. North America NGS Tumor Gene Analysis Software Revenue by Country (US$ Million) & (2027-2032) Table 109. Europe NGS Tumor Gene Analysis Software Revenue by Type (2021-2026) & (US$ Million) Table 110. Europe NGS Tumor Gene Analysis Software Revenue by Type (2027-2032) & (US$ Million) Table 111. Europe NGS Tumor Gene Analysis Software Revenue by Application (2021-2026) & (US$ Million) Table 112. Europe NGS Tumor Gene Analysis Software Revenue by Application (2027-2032) & (US$ Million) Table 113. Europe NGS Tumor Gene Analysis Software Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 114. Europe NGS Tumor Gene Analysis Software Revenue by Country (2021-2026) & (US$ Million) Table 115. Europe NGS Tumor Gene Analysis Software Revenue by Country (US$ Million) & (2027-2032) Table 116. China NGS Tumor Gene Analysis Software Revenue by Type (2021-2026) & (US$ Million) Table 117. China NGS Tumor Gene Analysis Software Revenue by Type (2027-2032) & (US$ Million) Table 118. China NGS Tumor Gene Analysis Software Revenue by Application (2021-2026) & (US$ Million) Table 119. China NGS Tumor Gene Analysis Software Revenue by Application (2027-2032) & (US$ Million) Table 120. Asia NGS Tumor Gene Analysis Software Revenue by Type (2021-2026) & (US$ Million) Table 121. Asia NGS Tumor Gene Analysis Software Revenue by Type (2027-2032) & (US$ Million) Table 122. Asia NGS Tumor Gene Analysis Software Revenue by Application (2021-2026) & (US$ Million) Table 123. Asia NGS Tumor Gene Analysis Software Revenue by Application (2027-2032) & (US$ Million) Table 124. Asia NGS Tumor Gene Analysis Software Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 125. Asia NGS Tumor Gene Analysis Software Revenue by Region (US$ Million) & (2021-2026) Table 126. Asia NGS Tumor Gene Analysis Software Revenue by Region (US$ Million) & (2027-2032) Table 127. SAMEA NGS Tumor Gene Analysis Software Revenue by Type (2021-2026) & (US$ Million) Table 128. SAMEA NGS Tumor Gene Analysis Software Revenue by Type (2027-2032) & (US$ Million) Table 129. SAMEA NGS Tumor Gene Analysis Software Revenue by Application (2021-2026) & (US$ Million) Table 130. SAMEA NGS Tumor Gene Analysis Software Revenue by Application (2027-2032) & (US$ Million) Table 131. SAMEA NGS Tumor Gene Analysis Software Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. SAMEA NGS Tumor Gene Analysis Software Revenue by Country (2021-2026) & (US$ Million) Table 133. SAMEA NGS Tumor Gene Analysis Software Revenue by Country (US$ Million) & (2027-2032) Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. NGS Tumor Gene Analysis Software Image Figure 2. Global NGS Tumor Gene Analysis Software Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global NGS Tumor Gene Analysis Software Market Size Share 2021 VS 2025 VS 2032 Figure 4. Non-Small Cell Lung Cancer Image Figure 5. Human 6 Gene Mutations Image Figure 6. Human 12 Gene Mutations Image Figure 7. Other Image Figure 8. Global NGS Tumor Gene Analysis Software Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global NGS Tumor Gene Analysis Software Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospitals and Health Systems Image Figure 11. Research Institute Image Figure 12. Other Image Figure 13. Global NGS Tumor Gene Analysis Software Market Size (US$ Million) & (2021-2032) Figure 14. Global NGS Tumor Gene Analysis Software Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global NGS Tumor Gene Analysis Software Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global NGS Tumor Gene Analysis Software Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global NGS Tumor Gene Analysis Software Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global NGS Tumor Gene Analysis Software Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global NGS Tumor Gene Analysis Software Revenue Market Share by Type (2021-2032) Figure 21. Global NGS Tumor Gene Analysis Software Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global NGS Tumor Gene Analysis Software Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global NGS Tumor Gene Analysis Software Revenue Market Share by Application (2021-2032) Figure 24. North America NGS Tumor Gene Analysis Software Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America NGS Tumor Gene Analysis Software Revenue Share by Type (2021-2032) Figure 26. North America NGS Tumor Gene Analysis Software Revenue Share by Application (2021-2032) Figure 27. North America NGS Tumor Gene Analysis Software Revenue Share by Country (2021-2032) Figure 28. United States NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe NGS Tumor Gene Analysis Software Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe NGS Tumor Gene Analysis Software Revenue Share by Type (2021-2032) Figure 33. Europe NGS Tumor Gene Analysis Software Revenue Share by Application (2021-2032) Figure 34. Europe NGS Tumor Gene Analysis Software Revenue Share by Country (2021-2032) Figure 35. Germany NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China NGS Tumor Gene Analysis Software Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China NGS Tumor Gene Analysis Software Revenue Share by Type (2021-2032) Figure 45. China NGS Tumor Gene Analysis Software Revenue Share by Application (2021-2032) Figure 46. Asia NGS Tumor Gene Analysis Software Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia NGS Tumor Gene Analysis Software Revenue Share by Type (2021-2032) Figure 48. Asia NGS Tumor Gene Analysis Software Revenue Share by Application (2021-2032) Figure 49. Asia NGS Tumor Gene Analysis Software Revenue Share by Region (2021-2032) Figure 50. Japan NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA NGS Tumor Gene Analysis Software Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA NGS Tumor Gene Analysis Software Revenue Share by Type (2021-2032) Figure 58. SAMEA NGS Tumor Gene Analysis Software Revenue Share by Application (2021-2032) Figure 59. SAMEA NGS Tumor Gene Analysis Software Revenue Share by Country (2021-2032) Figure 60. Brazil NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt NGS Tumor Gene Analysis Software Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Non-Small Cell Lung Cancer
  • Human 6 Gene Mutations
  • Human 12 Gene Mutations
  • Other
Applications
  • Hospitals and Health Systems
  • Research Institute
  • Other
Companies covered
  • Roche
  • Illumina
  • Thermo Fisher Scientific
  • BGI Group
  • Novogene
  • Geneseeq
  • AmoyDx
  • Burning Rock Medicine
  • GTH.O
  • Golden Helix, Inc
  • Diatech Pharmacogenetics
  • ViennaLab Diagnostics GmbH
  • 3D Medicines

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 NGS Tumor Gene Analysis Software Market by Type
  3. 1.2.1 Global NGS Tumor Gene Analysis Software Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Non-Small Cell Lung Cancer
  5. 1.2.3 Human 6 Gene Mutations
  6. 1.2.4 Human 12 Gene Mutations
  7. 1.2.5 Other
  8. 1.3 NGS Tumor Gene Analysis Software Market by Application
  9. 1.3.1 Global NGS Tumor Gene Analysis Software Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospitals and Health Systems
  11. 1.3.3 Research Institute
  12. 1.3.4 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 NGS Tumor Gene Analysis Software Market Dynamics
  1. 2.1 NGS Tumor Gene Analysis Software Industry Trends
  2. 2.2 NGS Tumor Gene Analysis Software Industry Drivers
  3. 2.3 NGS Tumor Gene Analysis Software Industry Opportunities and Challenges
  4. 2.4 NGS Tumor Gene Analysis Software Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global NGS Tumor Gene Analysis Software Market Perspective (2021-2032)
  2. 3.2 Global NGS Tumor Gene Analysis Software Growth Trends by Region
  3. 3.2.1 Global NGS Tumor Gene Analysis Software Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global NGS Tumor Gene Analysis Software Market Size by Region (2021-2026)
  5. 3.2.3 Global NGS Tumor Gene Analysis Software Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global NGS Tumor Gene Analysis Software Revenue by Players
  2. 4.1.1 Global NGS Tumor Gene Analysis Software Revenue by Players (2021-2026)
  3. 4.1.2 Global NGS Tumor Gene Analysis Software Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global NGS Tumor Gene Analysis Software Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global NGS Tumor Gene Analysis Software Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global NGS Tumor Gene Analysis Software Key Players Headquarters & Area Served
  7. 4.4 Global NGS Tumor Gene Analysis Software Players, Product Type & Application
  8. 4.5 Global NGS Tumor Gene Analysis Software Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global NGS Tumor Gene Analysis Software Market CR5 and HHI
  11. 4.6.3 2025 NGS Tumor Gene Analysis Software Tier 1, Tier 2, and Tier 3
5 NGS Tumor Gene Analysis Software Market Size by Type
  1. 5.1 Global NGS Tumor Gene Analysis Software Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global NGS Tumor Gene Analysis Software Revenue by Type (2021-2032)
  3. 5.3 Global NGS Tumor Gene Analysis Software Revenue Market Share by Type (2021-2032)
6 NGS Tumor Gene Analysis Software Market Size by Application
  1. 6.1 Global NGS Tumor Gene Analysis Software Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global NGS Tumor Gene Analysis Software Revenue by Application (2021-2032)
  3. 6.3 Global NGS Tumor Gene Analysis Software Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Roche
  2. 7.1.1 Roche Company Information
  3. 7.1.2 Roche Business Overview
  4. 7.1.3 Roche NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Roche NGS Tumor Gene Analysis Software Product Portfolio
  6. 7.1.5 Roche Recent Developments
  7. 7.2 Illumina
  8. 7.2.1 Illumina Company Information
  9. 7.2.2 Illumina Business Overview
  10. 7.2.3 Illumina NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Illumina NGS Tumor Gene Analysis Software Product Portfolio
  12. 7.2.5 Illumina Recent Developments
  13. 7.3 Thermo Fisher Scientific
  14. 7.3.1 Thermo Fisher Scientific Company Information
  15. 7.3.2 Thermo Fisher Scientific Business Overview
  16. 7.3.3 Thermo Fisher Scientific NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Thermo Fisher Scientific NGS Tumor Gene Analysis Software Product Portfolio
  18. 7.3.5 Thermo Fisher Scientific Recent Developments
  19. 7.4 BGI Group
  20. 7.4.1 BGI Group Company Information
  21. 7.4.2 BGI Group Business Overview
  22. 7.4.3 BGI Group NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  23. 7.4.4 BGI Group NGS Tumor Gene Analysis Software Product Portfolio
  24. 7.4.5 BGI Group Recent Developments
  25. 7.5 Novogene
  26. 7.5.1 Novogene Company Information
  27. 7.5.2 Novogene Business Overview
  28. 7.5.3 Novogene NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Novogene NGS Tumor Gene Analysis Software Product Portfolio
  30. 7.5.5 Novogene Recent Developments
  31. 7.6 Geneseeq
  32. 7.6.1 Geneseeq Company Information
  33. 7.6.2 Geneseeq Business Overview
  34. 7.6.3 Geneseeq NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Geneseeq NGS Tumor Gene Analysis Software Product Portfolio
  36. 7.6.5 Geneseeq Recent Developments
  37. 7.7 AmoyDx
  38. 7.7.1 AmoyDx Company Information
  39. 7.7.2 AmoyDx Business Overview
  40. 7.7.3 AmoyDx NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  41. 7.7.4 AmoyDx NGS Tumor Gene Analysis Software Product Portfolio
  42. 7.7.5 AmoyDx Recent Developments
  43. 7.8 Burning Rock Medicine
  44. 7.8.1 Burning Rock Medicine Company Information
  45. 7.8.2 Burning Rock Medicine Business Overview
  46. 7.8.3 Burning Rock Medicine NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Burning Rock Medicine NGS Tumor Gene Analysis Software Product Portfolio
  48. 7.8.5 Burning Rock Medicine Recent Developments
  49. 7.9 GTH.O
  50. 7.9.1 GTH.O Company Information
  51. 7.9.2 GTH.O Business Overview
  52. 7.9.3 GTH.O NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  53. 7.9.4 GTH.O NGS Tumor Gene Analysis Software Product Portfolio
  54. 7.9.5 GTH.O Recent Developments
  55. 7.10 Golden Helix, Inc
  56. 7.10.1 Golden Helix, Inc Company Information
  57. 7.10.2 Golden Helix, Inc Business Overview
  58. 7.10.3 Golden Helix, Inc NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Golden Helix, Inc NGS Tumor Gene Analysis Software Product Portfolio
  60. 7.10.5 Golden Helix, Inc Recent Developments
  61. 7.11 Diatech Pharmacogenetics
  62. 7.11.1 Diatech Pharmacogenetics Company Information
  63. 7.11.2 Diatech Pharmacogenetics Business Overview
  64. 7.11.3 Diatech Pharmacogenetics NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Diatech Pharmacogenetics NGS Tumor Gene Analysis Software Product Portfolio
  66. 7.11.5 Diatech Pharmacogenetics Recent Developments
  67. 7.12 ViennaLab Diagnostics GmbH
  68. 7.12.1 ViennaLab Diagnostics GmbH Company Information
  69. 7.12.2 ViennaLab Diagnostics GmbH Business Overview
  70. 7.12.3 ViennaLab Diagnostics GmbH NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  71. 7.12.4 ViennaLab Diagnostics GmbH NGS Tumor Gene Analysis Software Product Portfolio
  72. 7.12.5 ViennaLab Diagnostics GmbH Recent Developments
  73. 7.13 3D Medicines
  74. 7.13.1 3D Medicines Company Information
  75. 7.13.2 3D Medicines Business Overview
  76. 7.13.3 3D Medicines NGS Tumor Gene Analysis Software Revenue and Gross Margin (2021-2026)
  77. 7.13.4 3D Medicines NGS Tumor Gene Analysis Software Product Portfolio
  78. 7.13.5 3D Medicines Recent Developments
8 North America
  1. 8.1 North America NGS Tumor Gene Analysis Software Revenue (2021-2032)
  2. 8.2 North America NGS Tumor Gene Analysis Software Revenue by Type (2021-2032)
  3. 8.2.1 North America NGS Tumor Gene Analysis Software Revenue by Type (2021-2026)
  4. 8.2.2 North America NGS Tumor Gene Analysis Software Revenue by Type (2027-2032)
  5. 8.3 North America NGS Tumor Gene Analysis Software Revenue Share by Type (2021-2032)
  6. 8.4 North America NGS Tumor Gene Analysis Software Revenue by Application (2021-2032)
  7. 8.4.1 North America NGS Tumor Gene Analysis Software Revenue by Application (2021-2026)
  8. 8.4.2 North America NGS Tumor Gene Analysis Software Revenue by Application (2027-2032)
  9. 8.5 North America NGS Tumor Gene Analysis Software Revenue Share by Application (2021-2032)
  10. 8.6 North America NGS Tumor Gene Analysis Software Revenue by Country
  11. 8.6.1 North America NGS Tumor Gene Analysis Software Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America NGS Tumor Gene Analysis Software Revenue by Country (2021-2026)
  13. 8.6.3 North America NGS Tumor Gene Analysis Software Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe NGS Tumor Gene Analysis Software Revenue (2021-2032)
  2. 9.2 Europe NGS Tumor Gene Analysis Software Revenue by Type (2021-2032)
  3. 9.2.1 Europe NGS Tumor Gene Analysis Software Revenue by Type (2021-2026)
  4. 9.2.2 Europe NGS Tumor Gene Analysis Software Revenue by Type (2027-2032)
  5. 9.3 Europe NGS Tumor Gene Analysis Software Revenue Share by Type (2021-2032)
  6. 9.4 Europe NGS Tumor Gene Analysis Software Revenue by Application (2021-2032)
  7. 9.4.1 Europe NGS Tumor Gene Analysis Software Revenue by Application (2021-2026)
  8. 9.4.2 Europe NGS Tumor Gene Analysis Software Revenue by Application (2027-2032)
  9. 9.5 Europe NGS Tumor Gene Analysis Software Revenue Share by Application (2021-2032)
  10. 9.6 Europe NGS Tumor Gene Analysis Software Revenue by Country
  11. 9.6.1 Europe NGS Tumor Gene Analysis Software Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe NGS Tumor Gene Analysis Software Revenue by Country (2021-2026)
  13. 9.6.3 Europe NGS Tumor Gene Analysis Software Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China NGS Tumor Gene Analysis Software Revenue (2021-2032)
  2. 10.2 China NGS Tumor Gene Analysis Software Revenue by Type (2021-2032)
  3. 10.2.1 China NGS Tumor Gene Analysis Software Revenue by Type (2021-2026)
  4. 10.2.2 China NGS Tumor Gene Analysis Software Revenue by Type (2027-2032)
  5. 10.3 China NGS Tumor Gene Analysis Software Revenue Share by Type (2021-2032)
  6. 10.4 China NGS Tumor Gene Analysis Software Revenue by Application (2021-2032)
  7. 10.4.1 China NGS Tumor Gene Analysis Software Revenue by Application (2021-2026)
  8. 10.4.2 China NGS Tumor Gene Analysis Software Revenue by Application (2027-2032)
  9. 10.5 China NGS Tumor Gene Analysis Software Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia NGS Tumor Gene Analysis Software Revenue (2021-2032)
  2. 11.2 Asia NGS Tumor Gene Analysis Software Revenue by Type (2021-2032)
  3. 11.2.1 Asia NGS Tumor Gene Analysis Software Revenue by Type (2021-2026)
  4. 11.2.2 Asia NGS Tumor Gene Analysis Software Revenue by Type (2027-2032)
  5. 11.3 Asia NGS Tumor Gene Analysis Software Revenue Share by Type (2021-2032)
  6. 11.4 Asia NGS Tumor Gene Analysis Software Revenue by Application (2021-2032)
  7. 11.4.1 Asia NGS Tumor Gene Analysis Software Revenue by Application (2021-2026)
  8. 11.4.2 Asia NGS Tumor Gene Analysis Software Revenue by Application (2027-2032)
  9. 11.5 Asia NGS Tumor Gene Analysis Software Revenue Share by Application (2021-2032)
  10. 11.6 Asia NGS Tumor Gene Analysis Software Revenue by Country
  11. 11.6.1 Asia NGS Tumor Gene Analysis Software Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia NGS Tumor Gene Analysis Software Revenue by Country (2021-2026)
  13. 11.6.3 Asia NGS Tumor Gene Analysis Software Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA NGS Tumor Gene Analysis Software Revenue (2021-2032)
  2. 12.2 SAMEA NGS Tumor Gene Analysis Software Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA NGS Tumor Gene Analysis Software Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA NGS Tumor Gene Analysis Software Revenue by Type (2027-2032)
  5. 12.3 SAMEA NGS Tumor Gene Analysis Software Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA NGS Tumor Gene Analysis Software Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA NGS Tumor Gene Analysis Software Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA NGS Tumor Gene Analysis Software Revenue by Application (2027-2032)
  9. 12.5 SAMEA NGS Tumor Gene Analysis Software Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA NGS Tumor Gene Analysis Software Revenue by Country
  11. 12.6.1 SAMEA NGS Tumor Gene Analysis Software Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA NGS Tumor Gene Analysis Software Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA NGS Tumor Gene Analysis Software Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst